Effects of Magnolol combined with Gefitinib on A549 non-small cell lung cancer cells

doi:10.12047/j.cjap.6138.2021.076

Abstract

Abstract: Objective: To investigate the synergistic effects of magnolol and gefitinib on non-small cell lung cancer A549 cells. Methods: A549 cells were treated with Magnolol (6.25～500 μmol/L) or gefitinib (6.25～500 μmol/L) for 24 h, respectively, and the cell viability was detected by cell counting Kit-8 (CCK-8) experiment (n=3). Magnolol 100 μmol/L and gefitinib 5 μmol/L were selected in the following experiments (n=3, 24 h). Control group, magnolol group, gefitinib group and magnolol+gefitinib group were set up for factorial analysis. Colony formation experiment was applied to detect the cell proliferation. Western blot was used to detect protein expressions. Flow cytometry was applied to test cell apoptosis and sorting CD44⁺ and CD133⁺ cells. Results: Compared with the control group, the colony formation rate of Magnolol or Gefitinib groups was decreased significantly (P＜0.05); the apoptosis rate was increased significantly (P＜0.05); the number of CD44⁺ and CD133⁺ cells was reduced significantly (P＜0.05); the expressions of Ki67, PCNA, and stem cell marker proteins SOX2 and OCT4 were down-regulated (P＜0.05); and the ratio of Bax/Bcl-2 was increased significantly (P＜0.05). Compared with the Magnolol group or Gefitinib group, the Magnolol+Gefitinib group further promoted the above changes (P＜0.05), and the apoptosis rate, the ratio of Bax/Bcl-2, SOX2 and OCT4 all showed interactions between magnolol and gefitinib (P＜0.05). Conclusion: Magnolol and gefitinib promote the apoptosis of A549 cells and inhibit its stem cell-like properties, and the effect of the two combined is better than separated administration. Magnolol and gefitinib have interactive effects on A549 cells.

Key words: magnolol, stem cell like characteristics, Gefitinib, non-small cell lung cancer A549 cells

CLC Number:

R96
R734.2

REN Ji-lian, CUI Ling-zhi, HAO Xiao-xia, LI Xiao-yan, CHANG Yan-xiang. Effects of Magnolol combined with Gefitinib on A549 non-small cell lung cancer cells[J]. CJAP, 2021, 37(5): 506-510.

References

[1] Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454.
[2] 权建华, 张富利, 许卫东. 同步推量调强放疗联合多西他赛同期化疗治疗晚期非小细胞肺癌的临床效果及短期预后观察[J]. 临床误诊误治, 2020, 33(3): 72-76.
[3] 吴杨, 薛英杰, 贾靖. 阿法替尼联合不同化疗方案治疗晚期非小细胞肺癌的效果观察[J]. 解放军医药杂志, 2020, 32(11): 30-34.
[4] 田春艳, 李馥郁, 杨晋, 等. 吉非替尼联合吉西他滨和顺铂化疗方案治疗晚期非小细胞肺癌临床疗效及对血清肿瘤标志物的影响[J]. 解放军医药杂志, 2018, 30(4): 31-34.
[5] Kim Y, Lee SH, Ahn JS, et al. Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with Gefitinib or Erlotinib[J]. Cancer Res Treat,2019, 51(2): 502-509.
[6] Codony-Servat J, Codony-Servat C, Cardona AF, et al. Cancer stem cell biomarkers in EGFR-mutation-positive non-small-cell lung cancer[J]. Clin Lung Cancer, 2019, 20(3): 167-177.
[7] 林珊, 孟玲楠, 珊丹, 等. 不同靶向药物对EGFR表达异常的非小细胞肺癌细胞系放疗敏感性的影响[J]. 临床误诊误治, 2019, 32(9): 93-100.
[8] Ranaware AM, Banik K, Deshpande V, et al. Magnolol: A neolignan from the Magnolia family for the prevention and treatment of cancer[J]. Int J Mol Sci, 2018, 19(8): 2362.
[9] Tsai JR, Chong IW, Chen YH, et al. Magnolol induces apoptosis via caspase-independent pathways in non-small cell lung cancer cells[J]. Arch Pharm Res, 2014, 37(4): 548-557.
[10] Liu Y, Tong Y, Yang X, et al. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer[J]. Pharmacol Res, 2016, 111: 113-125.
[11] Shen J, Ma H, Zhang T, et al. Magnolol inhibits the growth of non-small cell lung cancer via inhibiting microtubule polymerization[J]. Cell Physiol Biochem, 2017, 42(5): 1789-1801.
[12] Kim GD, Oh J, Park HJ, et al. Magnolol inhibits angiogenesis by regulating ROS-mediated apoptosis and the PI3K/AKT/mTOR signaling pathway in mES/EB-derived endothelial-like cells[J]. Int J Oncol, 2013, 43(2): 600-610.
[13] 蒋盼若, 楼恩哲, 赵智祥, 等. 芹菜多糖抑制小鼠肺癌的作用研究[J]. 中国应用生理学杂志, 2019, 35(6): 551-554.
[14] 金鑫, 孙盼盼, 洪云, 等. 葛根素对人非小细胞肺癌A549细胞凋亡的作用[J]. 中国应用生理学杂志, 2017, 33(5): 466-469.
[15] Wang R, Luo Z, Zhang H, et al. Tanshinone IIA reverses Gefitinib-resistance in human non-small-cell lung cancer via regulation of VEGFR/Akt pathway[J]. Onco Targets Ther, 2019, 12: 9355-9365.